Impact of ERT and follow-up of 17 patients from the same family with a mild form of MPS II

dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSTEPHAN, Bruno de Oliveira
dc.contributor.authorQUAIO, Caio Robledo
dc.contributor.authorSPOLADOR, Gustavo Marquezani
dc.contributor.authorPAULA, Ana Carolina de
dc.contributor.authorCURIATI, Marco Antonio
dc.contributor.authorMARTINS, Ana Maria
dc.contributor.authorLEAL, Gabriela Nunes
dc.contributor.authorTENORIO, Artur
dc.contributor.authorFINZI, Simone
dc.contributor.authorCHIMELO, Flavia Teixeira
dc.contributor.authorMATAS, Carla Gentile
dc.contributor.authorHONJO, Rachel Sayuri
dc.contributor.authorBERTOLA, Debora Romeo
dc.contributor.authorKIM, Chong Ae
dc.date.accessioned2022-10-26T14:22:31Z
dc.date.available2022-10-26T14:22:31Z
dc.date.issued2022
dc.description.abstractBackground: Mucopolysaccharidosis type II, also known as Hunter syndrome, is a rare X-linked recessive disorder caused by deficiency of the lysosomal enzyme Iduronate-2-Sulfatase (IDS), leading to progressive accumulation of Glycosaminoglycans (GAGs) in several organs. Over the years, Enzyme Replacement Therapy (ERT) has provided significant benefits for patients, retarding the natural progression of the disease. Results: The authors evaluated 17 patients from the same family with a mild form of MPS type II; the proband had developed acute decompensated heart failure refractory to clinical measurements at 23 years and needed a rather urgent heart transplant; however, he died from surgical complications shortly after the procedure. Nevertheless, subsequent to his tragic death, 16 affected male relatives were detected after biochemical tests identifying the low or absent activity of the IDS enzyme and confirmed by molecular analysis of the IDS gene. Following diagnosis, different options of treatment were chosen: 6 patients started ERT with Elaprase (R) (Idursulfase) soon after, while the other 10 remained without ERT. Eventually, 4 patients in the latter group began ERT with Hunterase (R) (Idursulfase Beta). None presented adverse effects to either form of the enzyme. Among the 6 individuals without any ERT, two died of natural causes, after reaching 70 years. Despite the variable phenotype within the same family (mainly heart dysfunctions and carpal tunnel syndrome), all 14 remaining patients were alive with an independent lifestyle. Conclusion: Here, the authors report the variable progress of the disease with and without ERT in a large Brazilian family with a slowly progressive form of MPS II, harboring the same missense variant in the IDS gene.eng
dc.description.indexMEDLINEeng
dc.identifier.citationCLINICS, v.77, article ID 100082, 6p, 2022
dc.identifier.doi10.1016/j.clinsp.2022.100082
dc.identifier.eissn1980-5322
dc.identifier.issn1807-5932
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/49196
dc.language.isoeng
dc.publisherELSEVIER ESPANAeng
dc.relation.ispartofClinics
dc.rightsopenAccesseng
dc.rights.holderCopyright ELSEVIER ESPANAeng
dc.subject.otheridursulfase betaeng
dc.subject.otherhunter-syndromeeng
dc.subject.otherhearing-losseng
dc.subject.otherexperienceeng
dc.subject.otherchildreneng
dc.subject.otheradultseng
dc.subject.wosMedicine, General & Internaleng
dc.titleImpact of ERT and follow-up of 17 patients from the same family with a mild form of MPS IIeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalPAULA, Ana Carolina de:Univ Sao Paulo HCFMUSP, Inst Crianca, Hosp Clin, Fac Med, Sao Paulo, SP, Brazil
hcfmusp.author.externalCURIATI, Marco Antonio:Univ Sao Paulo HCFMUSP, Ctr Referencia Erros Inatos Metabol CREIM, Sao Paulo, SP, Brazil
hcfmusp.author.externalTENORIO, Artur:Univ Sao Paulo HCFMUSP, Fac Med, Hosp Clin, Oftalmol, Sao Paulo, SP, Brazil
hcfmusp.citation.scopus4
hcfmusp.contributor.author-fmusphcBRUNO DE OLIVEIRA STEPHAN
hcfmusp.contributor.author-fmusphcCAIO ROBLEDO D'ANGIOLI COSTA QUAIO
hcfmusp.contributor.author-fmusphcGUSTAVO MARQUEZANI SPOLADOR
hcfmusp.contributor.author-fmusphcANA MARIA MARTINS
hcfmusp.contributor.author-fmusphcGABRIELA NUNES LEAL
hcfmusp.contributor.author-fmusphcSIMONE FINZI
hcfmusp.contributor.author-fmusphcFLAVIA TEIXEIRA CHIMELO
hcfmusp.contributor.author-fmusphcCARLA GENTILE MATAS
hcfmusp.contributor.author-fmusphcRACHEL SAYURI HONJO KAWAHIRA
hcfmusp.contributor.author-fmusphcDEBORA ROMEO BERTOLA
hcfmusp.contributor.author-fmusphcCHONG AE KIM
hcfmusp.description.articlenumber100082
hcfmusp.description.volume77
hcfmusp.origemWOS
hcfmusp.origem.pubmed35882106
hcfmusp.origem.scieloSCIELO:S1807-59322022000100251
hcfmusp.origem.scopus2-s2.0-85134828411
hcfmusp.origem.wosWOS:000833592000004
hcfmusp.publisher.cityMADRIDeng
hcfmusp.publisher.countrySPAINeng
hcfmusp.relation.referenceAdam MP, 1993, DIABETES MELLITUS 6Qeng
hcfmusp.relation.referenceChung YK, 2014, GLYCOCONJUGATE J, V31, P309, DOI 10.1007/s10719-014-9523-0eng
hcfmusp.relation.referenceD'Avanzo F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041258eng
hcfmusp.relation.referenceGrinberg H, 2012, CARDIOVASC PATHOL, V21, P358, DOI 10.1016/j.carpath.2011.10.004eng
hcfmusp.relation.referenceKhan SA, 2018, MOL GENET METAB, V125, P44, DOI 10.1016/j.ymgme.2018.04.011eng
hcfmusp.relation.referenceKim C, 2017, J HUM GENET, V62, P167, DOI 10.1038/jhg.2016.133eng
hcfmusp.relation.referenceMarler JA, 2005, AM J MED GENET A, V138A, P318, DOI 10.1002/ajmg.a.30970eng
hcfmusp.relation.referenceMarler JA, 2010, AM J MED GENET C, V154C, P249, DOI 10.1002/ajmg.c.30262eng
hcfmusp.relation.referenceMartin R, 2008, PEDIATRICS, V121, pE377, DOI 10.1542/peds.2007-1350eng
hcfmusp.relation.referenceMuenzer J, 2011, GENET MED, V13, P95, DOI 10.1097/GIM.0b013e3181fea459eng
hcfmusp.relation.referenceMuenzer J, 2009, PEDIATRICS, V124, pE1228, DOI 10.1542/peds.2008-0999eng
hcfmusp.relation.referenceNgu LH, 2017, MOL GENET METAB REP, V12, P28, DOI 10.1016/j.ymgmr.2017.05.002eng
hcfmusp.relation.referenceomim, OMIM ONLINE MENDELIAeng
hcfmusp.relation.referenceorpha, **DROPPED REF**eng
hcfmusp.relation.referenceParini R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082975eng
hcfmusp.relation.referenceQuaio CRDC, 2012, JIMD REP, V4, P125, DOI 10.1007/8904_2011_90eng
hcfmusp.relation.referenceRichards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30eng
hcfmusp.relation.referenceSASAKI CT, 1987, LARYNGOSCOPE, V97, P280eng
hcfmusp.relation.referenceSemyachkina AN, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0807-xeng
hcfmusp.relation.referenceStapleton M, 2018, MOL GENET METAB, V125, P4, DOI 10.1016/j.ymgme.2018.01.003eng
hcfmusp.relation.referenceWraith JE, 2008, GENET MED, V10, P508, DOI [10.1097/GIM.0b013e31817701e6, 10.1097GIM.0b013e31817701e6]eng
hcfmusp.relation.referenceWraith JE, 2008, EUR J PEDIATR, V167, P267, DOI 10.1007/s00431-007-0635-4eng
hcfmusp.relation.referenceZarchi O, 2011, J PEDIATR-US, V158, P301, DOI 10.1016/j.jpeds.2010.07.056eng
hcfmusp.scopus.lastupdate2024-06-09
relation.isAuthorOfPublication81b47406-c05e-4ce6-bb8e-617a97df711d
relation.isAuthorOfPublicationd9d8ac9a-1d9b-4108-b1c8-c8888f486705
relation.isAuthorOfPublicationda411408-e128-47ee-995b-88f7b1344447
relation.isAuthorOfPublication32109840-b181-4488-95f9-3acd6008d384
relation.isAuthorOfPublicationa3b5e39d-525f-4648-87bb-229222d307ba
relation.isAuthorOfPublication0d4046a1-8068-4af8-84de-df60811353ff
relation.isAuthorOfPublication43500250-f121-47ae-a810-610860edce16
relation.isAuthorOfPublication0f675654-4d29-45dc-83ad-b227342d3a82
relation.isAuthorOfPublicationf71cc4f0-d44f-412c-a023-edf1c15c7bde
relation.isAuthorOfPublicationfc3f0957-77e4-44ad-8653-61f285bfcc94
relation.isAuthorOfPublication8715370a-1e5f-4af6-a1c4-ee31748e12a3
relation.isAuthorOfPublication.latestForDiscovery81b47406-c05e-4ce6-bb8e-617a97df711d
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
art_STEPHAN_Impact_of_ERT_and_followup_of_17_patients_2022.PDF
Tamanho:
449 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)